OpenLB
Open Library of Bioscience
Advanced Search
International journal of molecular sciences
Aug 24, 2024;25 (17):

The Current State of Realistic Heart Models for Disease Modelling and Cardiotoxicity.

Kornél Kistamás, Federica Lamberto, Raminta Vaiciuleviciute, Filipa Leal, Suchitra Muenthaisong, Luis Marte, Paula Subías-Beltrán, Aidas Alaburda, Dina N Arvanitis, Melinda Zana, Pedro F Costa, Eiva Bernotiene, Christian Bergaud, András Dinnyés
Author Information
  1. Kornél Kistamás: BioTalentum Ltd., Aulich Lajos Str 26, H-2100 Gödöllő, Hungary. ORCID
  2. Federica Lamberto: BioTalentum Ltd., Aulich Lajos Str 26, H-2100 Gödöllő, Hungary. ORCID
  3. Raminta Vaiciuleviciute: Department of Regenerative Medicine, State Research Institute Innovative Medicine Centre, Santariskiu g. 5, LT-08406 Vilnius, Lithuania. ORCID
  4. Filipa Leal: Biofabics Lda, Rua Alfredo Allen 455, 4200-135 Porto, Portugal.
  5. Suchitra Muenthaisong: BioTalentum Ltd., Aulich Lajos Str 26, H-2100 Gödöllő, Hungary.
  6. Luis Marte: Digital Health Unit, Eurecat-Centre Tecnològic de Catalunya, 08005 Barcelona, Spain. ORCID
  7. Paula Subías-Beltrán: Digital Health Unit, Eurecat-Centre Tecnològic de Catalunya, 08005 Barcelona, Spain. ORCID
  8. Aidas Alaburda: Department of Regenerative Medicine, State Research Institute Innovative Medicine Centre, Santariskiu g. 5, LT-08406 Vilnius, Lithuania. ORCID
  9. Dina N Arvanitis: Laboratory for Analysis and Architecture of Systems-French National Centre for Scientific Research (LAAS-CNRS), 7 Avenue du Colonel Roche, F-31400 Toulouse, France.
  10. Melinda Zana: BioTalentum Ltd., Aulich Lajos Str 26, H-2100 Gödöllő, Hungary. ORCID
  11. Pedro F Costa: Biofabics Lda, Rua Alfredo Allen 455, 4200-135 Porto, Portugal. ORCID
  12. Eiva Bernotiene: Department of Regenerative Medicine, State Research Institute Innovative Medicine Centre, Santariskiu g. 5, LT-08406 Vilnius, Lithuania.
  13. Christian Bergaud: Laboratory for Analysis and Architecture of Systems-French National Centre for Scientific Research (LAAS-CNRS), 7 Avenue du Colonel Roche, F-31400 Toulouse, France.
  14. András Dinnyés: BioTalentum Ltd., Aulich Lajos Str 26, H-2100 Gödöllő, Hungary. ORCID
PMID: 39273136 DOI: 10.3390/ijms25179186

Abstract

One of the many unresolved obstacles in the field of cardiovascular research is an uncompromising in vitro cardiac model. While primary cell sources from animal models offer both advantages and disadvantages, efforts over the past half-century have aimed to reduce their use. Additionally, obtaining a sufficient quantity of human primary cardiomyocytes faces ethical and legal challenges. As the practically unlimited source of human cardiomyocytes from induced pluripotent stem cells (hiPSC-CM) is now mostly resolved, there are great efforts to improve their quality and applicability by overcoming their intrinsic limitations. The greatest bottleneck in the field is the in vitro ageing of hiPSC-CMs to reach a maturity status that closely resembles that of the adult heart, thereby allowing for more appropriate drug developmental procedures as there is a clear correlation between ageing and developing cardiovascular diseases. Here, we review the current state-of-the-art techniques in the most realistic heart models used in disease modelling and toxicity evaluations from hiPSC-CM maturation through heart-on-a-chip platforms and in silico models to the in vitro models of certain cardiovascular diseases.

Keywords

cardiac model cardiomyocyte cardiomyocyte maturation disease modelling drug testing heart-on-a-chip hiPSC-CM toxicology

References

  1. J Physiol. 1952 Apr;116(4):449-72 [PMID: 14946713]
  2. Mol Ther Methods Clin Dev. 2021 May 21;22:338-349 [PMID: 34514026]
  3. J Mol Cell Cardiol. 2022 Apr;165:19-30 [PMID: 34959166]
  4. Proc Natl Acad Sci U S A. 2021 Sep 14;118(37): [PMID: 34493665]
  5. SN Appl Sci. 2020;2(2):276 [PMID: 32803125]
  6. Environ Toxicol. 2023 Sep;38(9):2165-2172 [PMID: 37357850]
  7. Circulation. 2020 Oct 13;142(15):e214-e233 [PMID: 32929996]
  8. Front Cardiovasc Med. 2022 Aug 12;9:966094 [PMID: 36035948]
  9. JACC Basic Transl Sci. 2018 Dec 31;3(6):728-740 [PMID: 30623132]
  10. Front Genet. 2022 Apr 14;13:891159 [PMID: 35495144]
  11. Curr Treat Options Oncol. 2021 Feb 5;22(2):18 [PMID: 33547494]
  12. Cardiovasc Res. 2011 May 1;90(2):194-201 [PMID: 21502371]
  13. Br J Pharmacol. 2015 Nov;172(21):5147-60 [PMID: 26276951]
  14. Nat Commun. 2020 Jan 7;11(1):75 [PMID: 31911598]
  15. Front Physiol. 2016 Oct 18;7:467 [PMID: 27803673]
  16. Biofabrication. 2022 Oct 28;15(1): [PMID: 36195063]
  17. Adv Drug Deliv Rev. 2020;165-166:60-76 [PMID: 31917972]
  18. Eur Heart J. 2019 Oct 1;40(37):3081-3094 [PMID: 31114854]
  19. Front Physiol. 2017 Dec 12;8:986 [PMID: 29311950]
  20. Stem Cells Int. 2022 Dec 19;2022:9438281 [PMID: 36579142]
  21. Cell Stem Cell. 2012 Jan 6;10(1):16-28 [PMID: 22226352]
  22. Front Cardiovasc Med. 2022 May 13;9:889519 [PMID: 35647048]
  23. Am J Physiol Heart Circ Physiol. 2023 May 1;324(5):H675-H685 [PMID: 36930654]
  24. J Physiol. 2019 Sep;597(17):4533-4564 [PMID: 31278749]
  25. Int J Stem Cells. 2022 Aug 30;15(3):247-257 [PMID: 35220280]
  26. Heart Fail Rev. 2019 Mar;24(2):167-176 [PMID: 30565021]
  27. Stem Cells Transl Med. 2022 Oct 21;11(10):1040-1051 [PMID: 36018047]
  28. Front Cell Dev Biol. 2024 Jan 18;12:1298007 [PMID: 38304423]
  29. STAR Protoc. 2020 Jun 19;1(1): [PMID: 32734277]
  30. Circ Res. 2003 Jul 11;93(1):32-9 [PMID: 12791707]
  31. J Pharmacol Toxicol Methods. 2016 Sep-Oct;81:251-62 [PMID: 27060526]
  32. Int J Mol Sci. 2020 Jan 19;21(2): [PMID: 31963859]
  33. Nature. 2012 Sep 13;489(7415):322-5 [PMID: 22864415]
  34. JACC Clin Electrophysiol. 2022 Mar;8(3):386-405 [PMID: 35331438]
  35. JACC Cardiovasc Interv. 2016 Oct 24;9(20):2157-2164 [PMID: 27765312]
  36. iScience. 2022 Apr 29;25(5):104330 [PMID: 35602954]
  37. Korean J Pediatr. 2014 Jan;57(1):1-18 [PMID: 24578711]
  38. Cardiovasc Res. 2012 Sep 1;95(4):419-29 [PMID: 22739119]
  39. PLoS One. 2016 Mar 28;11(3):e0151461 [PMID: 27019293]
  40. Biomed Pharmacother. 2023 Jan;157:113970 [PMID: 36371854]
  41. Circ Res. 2017 May 12;120(10):1572-1583 [PMID: 28400398]
  42. Cell Rep. 2018 Sep 25;24(13):3582-3592 [PMID: 30257217]
  43. Am J Cardiol. 1995 May 15;75(15):1023-7 [PMID: 7747682]
  44. Int J Mol Sci. 2021 Jan 11;22(2): [PMID: 33440843]
  45. Clin Pharmacol Ther. 2019 Sep;106(3):642-651 [PMID: 30947366]
  46. Front Cell Dev Biol. 2019 Aug 09;7:164 [PMID: 31448277]
  47. Am J Cardiol. 1998 Apr 1;81(7):869-76 [PMID: 9555777]
  48. Stem Cell Reports. 2018 Aug 14;11(2):522-536 [PMID: 30033088]
  49. J Physiol Anthropol. 2016 Sep 28;35(1):22 [PMID: 27680542]
  50. Int J Mol Sci. 2021 Mar 16;22(6): [PMID: 33809429]
  51. Biochem Pharmacol. 2021 Oct;192:114746 [PMID: 34461117]
  52. Acta Biomater. 2017 Jan 15;48:20-40 [PMID: 27826001]
  53. Wellcome Open Res. 2016 Nov 15;1:6 [PMID: 27918599]
  54. Acta Pharmacol Sin. 2023 Feb;44(2):259-267 [PMID: 35715699]
  55. Comput Math Methods Med. 2019 Nov 12;2019:8237071 [PMID: 31827590]
  56. Nat Methods. 2022 Sep;19(9):1064-1071 [PMID: 36064773]
  57. Exp Ther Med. 2022 Dec 09;25(1):61 [PMID: 36588805]
  58. JCI Insight. 2018 Jun 21;3(12): [PMID: 29925689]
  59. JCI Insight. 2021 May 24;6(10): [PMID: 33878037]
  60. Toxicol In Vitro. 2020 Sep;67:104891 [PMID: 32446838]
  61. Biol Open. 2020 Sep 21;9(9): [PMID: 32878883]
  62. Cells. 2022 Mar 19;11(6): [PMID: 35326497]
  63. Bioengineering (Basel). 2022 Jan 13;9(1): [PMID: 35049741]
  64. Am J Physiol Heart Circ Physiol. 2006 Sep;291(3):H1273-80 [PMID: 16565313]
  65. Cells. 2023 May 11;12(10): [PMID: 37408197]
  66. Stem Cell Res Ther. 2021 May 7;12(1):278 [PMID: 33962658]
  67. Circ Res. 2019 Apr 12;124(8):1172-1183 [PMID: 30700234]
  68. Sci Rep. 2024 Jan 31;14(1):2586 [PMID: 38297132]
  69. Eur Heart J. 2005 Mar;26(6):590-7 [PMID: 15637086]
  70. Dis Model Mech. 2024 Apr 1;17(4): [PMID: 38516812]
  71. Cell Rep Med. 2021 Mar 16;2(3):100216 [PMID: 33763655]
  72. Front Cell Dev Biol. 2023 Feb 07;11:1075917 [PMID: 36824370]
  73. Eur J Pharm Sci. 2009 Jan 31;36(1):62-77 [PMID: 19061955]
  74. Sci Rep. 2020 Oct 12;10(1):16977 [PMID: 33046816]
  75. Int J Mol Sci. 2024 Mar 28;25(7): [PMID: 38612582]
  76. Br J Pharmacol. 2015 Aug;172(16):4002-11 [PMID: 26031452]
  77. Pflugers Arch. 2015 Jul;467(7):1431-1443 [PMID: 25081243]
  78. Cardioscience. 1994 Sep;5(3):203-8 [PMID: 7827258]
  79. Cell Stem Cell. 2020 Jun 4;26(6):862-879.e11 [PMID: 32459996]
  80. Nature. 2016 Oct 20;538(7625):388-391 [PMID: 27723741]
  81. PLoS One. 2020 Mar 10;15(3):e0230001 [PMID: 32155214]
  82. Cell. 2019 Feb 7;176(4):913-927.e18 [PMID: 30686581]
  83. Genes (Basel). 2021 Sep 30;12(10): [PMID: 34680959]
  84. Stem Cell Reports. 2022 Mar 8;17(3):556-568 [PMID: 35148844]
  85. Biomedicines. 2021 May 18;9(5): [PMID: 34069816]
  86. Cell Rep. 2020 Jul 21;32(3):107925 [PMID: 32697997]
  87. PLoS Comput Biol. 2021 Oct 6;17(10):e1009443 [PMID: 34613960]
  88. Front Physiol. 2021 Jun 16;12:675867 [PMID: 34220540]
  89. Am J Physiol Heart Circ Physiol. 2015 Nov;309(9):H1453-67 [PMID: 26386112]
  90. Adv Drug Deliv Rev. 2016 Jan 15;96:253-73 [PMID: 26788696]
  91. Front Cardiovasc Med. 2022 Aug 16;9:950829 [PMID: 36051285]
  92. Front Cardiovasc Med. 2020 Feb 14;7:14 [PMID: 32118049]
  93. Circ Res. 2020 Jun 19;127(1):4-20 [PMID: 32716709]
  94. Trends Biotechnol. 2023 Mar;41(3):410-424 [PMID: 36725464]
  95. Eur Heart J. 2019 Jun 7;40(22):1771-1777 [PMID: 29982507]
  96. Sci Rep. 2015 Mar 09;5:8883 [PMID: 25748532]
  97. PLoS Comput Biol. 2021 Feb 16;17(2):e1008089 [PMID: 33591962]
  98. PLoS Comput Biol. 2021 Aug 12;17(8):e1009233 [PMID: 34383746]
  99. Stem Cell Reports. 2023 Nov 14;18(11):2096-2107 [PMID: 37922915]
  100. Elife. 2021 Aug 02;10: [PMID: 34338636]
  101. Stem Cell Res Ther. 2023 Sep 8;14(1):241 [PMID: 37679791]
  102. J Mol Cell Cardiol. 2013 Mar;56:34-43 [PMID: 23220154]
  103. J Mol Cell Cardiol. 2016 Aug;97:245-62 [PMID: 27262674]
  104. Lancet. 2010 Sep 11;376(9744):886-94 [PMID: 20801495]
  105. Eur Heart J. 2019 Dec 1;40(45):3685-3695 [PMID: 31219556]
  106. Bioengineering (Basel). 2018 May 04;5(2): [PMID: 29734702]
  107. J Pers Med. 2023 Aug 08;13(8): [PMID: 37623487]
  108. Tissue Eng Part A. 2023 Jun;29(11-12):322-332 [PMID: 36855326]
  109. Stem Cells Dev. 2015 May 1;24(9):1035-52 [PMID: 25583389]
  110. Am J Pathol. 2003 Sep;163(3):1081-90 [PMID: 12937148]
  111. J Thorac Dis. 2019 Mar;11(3):1005-1015 [PMID: 31019790]
  112. Nat Protoc. 2018 Dec;13(12):3018-3041 [PMID: 30413796]
  113. Sci Rep. 2021 Feb 18;11(1):4153 [PMID: 33603154]
  114. Int J Mol Sci. 2020 Jun 19;21(12): [PMID: 32575374]
  115. Front Physiol. 2012 Aug 31;3:346 [PMID: 23015789]
  116. J Vis Exp. 2020 May 5;(159): [PMID: 32449739]
  117. Nat Rev Cardiol. 2018 Jul;15(7):387-407 [PMID: 29674714]
  118. Sci Rep. 2021 Feb 4;11(1):3026 [PMID: 33542270]
  119. Int J Mol Sci. 2020 May 11;21(9): [PMID: 32403456]
  120. Nat Commun. 2022 Nov 26;13(1):7301 [PMID: 36435871]
  121. N Engl J Med. 1991 Mar 21;324(12):781-8 [PMID: 1900101]
  122. Front Pharmacol. 2020 Feb 25;11:72 [PMID: 32161540]
  123. J Cardiovasc Dev Dis. 2019 Apr 27;6(2): [PMID: 31035613]
  124. Stem Cell Reports. 2021 Mar 9;16(3):519-533 [PMID: 33636116]
  125. Nat Rev Drug Discov. 2023 Apr;22(4):317-335 [PMID: 36781957]
  126. Nature. 2018 Apr;556(7700):239-243 [PMID: 29618819]
  127. Circ Res. 2009 Feb 27;104(4):e30-41 [PMID: 19213953]
  128. Evid Based Complement Alternat Med. 2022 Feb 25;2022:7781910 [PMID: 35251212]
  129. Microsyst Nanoeng. 2022 Feb 28;8:26 [PMID: 35299653]
  130. Cell Death Dis. 2022 May 9;13(5):444 [PMID: 35534453]
  131. Semin Perinatol. 2023 Apr;47(3):151729 [PMID: 37012138]
  132. J Am Heart Assoc. 2018 Mar 24;7(7): [PMID: 29574456]
  133. Eur Heart J. 2021 Feb 1;42(5):373-498 [PMID: 32860505]
  134. Anal Bioanal Chem. 2023 Jul;415(18):3911-3925 [PMID: 36867198]
  135. Sci Rep. 2021 Aug 4;11(1):15845 [PMID: 34349150]
  136. Environ Pollut. 2023 Oct 15;335:122359 [PMID: 37567409]
  137. Front Pharmacol. 2021 May 21;12:615424 [PMID: 34093174]
  138. J Pharmacol Sci. 2019 Aug;140(4):313-316 [PMID: 31113731]
  139. Circulation. 2020 Sep 15;142(11):1059-1076 [PMID: 32623905]
  140. Circ Cardiovasc Genet. 2015 Aug;8(4):582-95 [PMID: 25904541]
  141. PLoS One. 2015 Sep 22;10(9):e0138849 [PMID: 26393803]
  142. BMJ. 2011 Jun 17;342:d3527 [PMID: 21685437]
  143. Pflugers Arch. 2018 Feb;470(2):241-248 [PMID: 28849267]
  144. J Pharmacol Toxicol Methods. 2016 Sep-Oct;81:15-20 [PMID: 27282641]
  145. STAR Protoc. 2022 Aug 18;3(3):101560 [PMID: 36035804]
  146. Biochem Biophys Res Commun. 2020 Dec 10;533(3):376-382 [PMID: 32962862]
  147. Cell Rep. 2014 Nov 6;9(3):810-21 [PMID: 25437537]
  148. Biomedicines. 2023 Aug 23;11(9): [PMID: 37760796]
  149. Circ Res. 2018 Jul 6;123(2):224-243 [PMID: 29976690]
  150. Nature. 2020 Dec;588(7838):466-472 [PMID: 32971526]
  151. Stem Cell Reports. 2018 Dec 11;11(6):1378-1390 [PMID: 30416051]
  152. Sci Bull (Beijing). 2023 May 15;68(9):938-945 [PMID: 37062651]
  153. Nature. 2011 Mar 10;471(7337):230-4 [PMID: 21307850]
  154. J Physiol Pharmacol. 2015 Feb;66(1):73-81 [PMID: 25716967]
  155. Stem Cell Reports. 2020 Oct 13;15(4):999-1013 [PMID: 32976766]
  156. Cell Physiol Biochem. 2011;28(4):579-92 [PMID: 22178870]
  157. Cardiovasc Res. 2020 May 1;116(6):1147-1160 [PMID: 31504264]
  158. Cell Rep. 2024 Jun 25;43(6):114302 [PMID: 38824644]
  159. Biomaterials. 2014 Jul;35(21):5462-71 [PMID: 24731714]
  160. Circulation. 2007 Nov 13;116(20):2325-45 [PMID: 17998470]
  161. Clin Pharmacol Ther. 2019 Apr;105(4):943-953 [PMID: 30447156]
  162. Life (Basel). 2022 Feb 16;12(2): [PMID: 35207580]
  163. Chemosphere. 2024 Apr;353:141567 [PMID: 38417488]
  164. Cell Rep. 2023 Apr 25;42(4):112330 [PMID: 37014753]
  165. Ann N Y Acad Sci. 2006 Oct;1080:395-414 [PMID: 17132797]
  166. Circ Res. 2021 Mar 19;128(6):775-801 [PMID: 33734815]
  167. J Toxicol Sci. 2017;42(4):519-527 [PMID: 28717111]
  168. Ann Biomed Eng. 2021 Jan;49(1):129-138 [PMID: 32367466]
  169. Future Cardiol. 2013 Jan;9(1):71-88 [PMID: 23259476]
  170. Biol Res. 2021 Feb 5;54(1):3 [PMID: 33546773]
  171. N Engl J Med. 2021 Jan 14;384(2):117-128 [PMID: 33200892]
  172. Front Pharmacol. 2021 Aug 03;12:680618 [PMID: 34413773]
  173. Front Physiol. 2022 Oct 11;13:1002203 [PMID: 36304573]
  174. Biochem Biophys Res Commun. 2020 Jun 4;526(3):751-755 [PMID: 32265031]
  175. Clin Pharmacol Ther. 2019 Feb;105(2):466-475 [PMID: 30151907]
  176. Stem Cells. 2022 Jun 22;40(6):537-545 [PMID: 35303744]
  177. JACC Heart Fail. 2020 Nov;8(11):931-939 [PMID: 33039447]
  178. Nat Protoc. 2019 Oct;14(10):2781-2817 [PMID: 31492957]
  179. PLoS One. 2014 Apr 14;9(4):e94722 [PMID: 24733085]
  180. Toxicol Appl Pharmacol. 2015 May 15;285(1):51-60 [PMID: 25841593]
  181. Front Cell Dev Biol. 2022 Nov 28;10:895162 [PMID: 36518540]
  182. J Mol Cell Cardiol. 2021 Sep;158:153-162 [PMID: 34089737]
  183. J Mol Cell Cardiol. 2018 May;118:147-158 [PMID: 29604261]
  184. Cell. 2007 Nov 30;131(5):861-72 [PMID: 18035408]
  185. Elife. 2021 Jul 02;10: [PMID: 34212860]
  186. Stem Cell Reports. 2021 Jun 8;16(6):1542-1554 [PMID: 34019817]
  187. Sci Adv. 2024 Jan 19;10(3):eadg1222 [PMID: 38241367]
  188. Stem Cell Res Ther. 2023 Jul 27;14(1):183 [PMID: 37501071]
  189. Stem Cells. 2020 Jul;38(7):822-833 [PMID: 32232889]
  190. STAR Protoc. 2020 Jun 03;1(1):100026 [PMID: 33111079]
  191. Stem Cell Reports. 2021 Sep 14;16(9):2049-2057 [PMID: 33338434]
  192. ACS Appl Mater Interfaces. 2018 Jun 27;10(25):21173-21183 [PMID: 29874032]
  193. Int J Mol Sci. 2021 Dec 21;23(1): [PMID: 35008432]
  194. J Pharmacol Toxicol Methods. 2020 Sep;105:106895 [PMID: 32629158]
  195. Biotechnol Adv. 2024 Jan-Feb;70:108293 [PMID: 37984683]
  196. J Physiol. 2017 Aug 15;595(16):5545-5555 [PMID: 28617952]
  197. Front Cardiovasc Med. 2020 Mar 31;7:43 [PMID: 32296716]
  198. Stem Cell Res Ther. 2022 Jul 23;13(1):332 [PMID: 35870954]
  199. Stem Cell Res. 2020 Dec;49:102043 [PMID: 33128951]
  200. Stem Cell Res Ther. 2020 Nov 5;11(1):470 [PMID: 33153480]
  201. Eur Heart J. 2018 Apr 21;39(16):1446-1455 [PMID: 29020304]
  202. PLoS One. 2014 Sep 25;9(9):e108051 [PMID: 25255322]
  203. Europace. 2019 Jul 1;21(7):993-994 [PMID: 30882143]
  204. Lancet. 2022 Dec 3;400(10367):1927-1937 [PMID: 36356632]
  205. Circ Arrhythm Electrophysiol. 2013 Feb;6(1):191-201 [PMID: 23392582]
  206. Adv Healthc Mater. 2024 May;13(13):e2303288 [PMID: 38349615]
  207. Front Pharmacol. 2020 Aug 21;11:1314 [PMID: 32973530]
  208. Arch Toxicol. 2021 Dec;95(12):3633-3650 [PMID: 34657219]
  209. Stem Cells Int. 2019 Mar 6;2019:7532657 [PMID: 30956674]
  210. Sci Robot. 2018 Mar 28;3(16): [PMID: 33141750]
  211. Circulation. 2018 Dec 4;138(23):2666-2681 [PMID: 29914921]
  212. Circ Res. 2017 Jul 7;121(2):181-195 [PMID: 28684623]
  213. Circ Res. 2013 Mar 15;112(6):969-76; discussion 976 [PMID: 23569106]
  214. Lab Chip. 2017 May 16;17(10):1732-1739 [PMID: 28448074]
  215. PLoS One. 2022 May 26;17(5):e0266647 [PMID: 35617323]
  216. Adv Sci (Weinh). 2022 May;9(16):e2105777 [PMID: 35347883]
  217. Basic Res Cardiol. 2023 Apr 5;118(1):14 [PMID: 37020075]
  218. Eur J Heart Fail. 2021 Feb;23(2):277-285 [PMID: 33070419]
  219. Europace. 2016 Dec;18(suppl 4):iv67-iv76 [PMID: 28011833]
  220. J Am Coll Cardiol. 2020 Dec 22;76(25):2982-3021 [PMID: 33309175]
  221. Front Physiol. 2015 Feb 03;6:7 [PMID: 25691870]
  222. Lancet. 2020 Sep 12;396(10253):759-769 [PMID: 32871100]
  223. Circ Res. 2012 Oct 12;111(9):1125-36 [PMID: 22912385]
  224. Nature. 2014 Jun 12;510(7504):273-7 [PMID: 24776797]
  225. Nat Commun. 2020 Jan 27;11(1):535 [PMID: 31988308]
  226. Methods Mol Biol. 2016;1386:331-50 [PMID: 26677190]
  227. Nat Mater. 2017 Mar;16(3):303-308 [PMID: 27775708]
  228. N Engl J Med. 1992 Jul 23;327(4):227-33 [PMID: 1377359]
  229. Front Cell Dev Biol. 2022 Mar 31;10:855763 [PMID: 35433691]
  230. Circulation. 2014 Mar 11;129(10):1092-103 [PMID: 24352520]
  231. Sci Rep. 2020 Nov 5;10(1):19201 [PMID: 33154509]

Grants

  1. No. 953138/EU Horizon 2020
  2. No. 812660/EU Horizon 2020
  3. No. 2020-1.1.5-GYORSÍTÓSÁV-2021-00016/Hungarian National Research, Development and Innovation Fund

MeSH Term

Humans
Cardiotoxicity
Induced Pluripotent Stem Cells
Myocytes, Cardiac
Animals
Cell Differentiation
Cardiovascular Diseases
Models, Cardiovascular
Journal Article Review

Word Cloud

Created with Highcharts 10.0.0modelscardiovascularvitrohiPSC-CMfieldcardiacmodelprimaryeffortshumancardiomyocytesageingheartdrugdiseasesdiseasemodellingmaturationheart-on-a-chipcardiomyocyteOnemanyunresolvedobstaclesresearchuncompromisingcellsourcesanimalofferadvantagesdisadvantagespasthalf-centuryaimedreduceuseAdditionallyobtainingsufficientquantityfacesethicallegalchallengespracticallyunlimitedsourceinducedpluripotentstemcellsnowmostlyresolvedgreatimprovequalityapplicabilityovercomingintrinsiclimitationsgreatestbottleneckhiPSC-CMsreachmaturitystatuscloselyresemblesadulttherebyallowingappropriatedevelopmentalproceduresclearcorrelationdevelopingreviewcurrentstate-of-the-arttechniquesrealisticusedtoxicityevaluationsplatformssilicocertainCurrentStateRealisticHeartModelsDiseaseModellingCardiotoxicitytestingtoxicology

Similar Articles

Cited By